research Tyrosine Kinase Inhibitors: A Review on Pharmacology, Metabolism, and Side Effects
Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
Search
for
Sort by
Research
30 / 1000+ resultsresearch Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
research Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
research Adverse Cutaneous Reactions to the New Second-Generation Tyrosine Kinase Inhibitors (Dasatinib, Nilotinib) in Chronic Myeloid Leukemia
Many patients on new leukemia drugs had mild to moderate skin reactions.
research A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib
A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.
research Repigmentation of Leukoderma in a Piebald Patient Associated with a Novel c-KIT Gene Mutation, G592E, of the Tyrosine Kinase Domain
A new gene mutation may allow some piebaldism patients to regain skin color in white patches.
research Tyrosine Kinase Inhibitors in Dermatology: A Systematic Review
Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
research Characterization, Genomic Organization, Expression, and Function of the mEphA1 Receptor Tyrosine Kinase
mEphA1 receptor tyrosine kinase is important for skin and hair development and may play a role in certain diseases.
research Keratosis Pilaris-Like Eruption During Chronic Myeloid Leukemia Treatment With Tyrosine Kinase Inhibitors: A Literature Review And Case Report On Imatinib
Some leukemia treatments can cause skin reactions similar to keratosis pilaris.
research Preclinical Evidence Supporting Selective Inhibition of Tyrosine Kinase 2-Dependent, IL-12-Mediated Signaling as a Novel Strategy for Alopecia Areata Management
Blocking TYK2 might be a new way to treat hair loss from alopecia areata.
research Tyrosine Kinase 2 Inhibition Ameliorates the Phenotype of Lesional Alopecia Areata Scalp Skin Ex Vivo, and Reverses the Induction of Human Alopecia Areata in a Humanized Mouse Model
TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.
research Tyrosine Kinase 2 Inhibition Rescues Hair Follicles From IL-12-Mediated Immune Privilege Collapse And Reverses Human Alopecia Areata In A Humanized Mouse Model
Inhibiting TYK2 can restore hair growth in alopecia areata.
research Selective Inhibition of Tyrosine Kinase 2 Prevents and Restores Interleukin-12-Induced Hair Follicle Immune Privilege Collapse: A Novel Approach to Alopecia Areata Therapy?
Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
research Tyrosine Kinase Inhibitors Against Cancer: Their Safety in 216 Moroccan Patients
Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
research Cutaneous and Mucosal Side Effects of New Anticancer Drugs: EGF-R Inhibitors, Tyrosine Kinase Inhibitors, and Mitotic Spindle Stabilizers
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
research Bioinformatic Analysis of Gene Expression Data Reveals Src Family Protein Tyrosine Kinases as Key Players in Androgenetic Alopecia
Protein tyrosine kinases are key in male pattern baldness, affecting skin structure, hair growth, and immune responses.
research Taiwanese Dermatological Association Consensus for the Prevention and Management of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Related Skin Toxicities
The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.
research Acneiform Eruptions Caused by an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor ZD1839
ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
research Platycladus Orientalis Leaf Extract Promotes Hair Growth Via Non-Receptor Tyrosine Kinase ACK1 Activation
Platycladus orientalis leaf extract helps hair grow by activating certain proteins.
research Comparison of Pemetrexed and Docetaxel as Salvage Chemotherapy for the Treatment of Non-Small-Cell Lung Cancer After the Failure of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
Pemetrexed is as effective as docetaxel but has fewer side effects for treating nonsmall-cell lung cancer after EGFR-TKI therapy failure.
research Human Dermal Fibroblasts and Mast Cell Populations Are Altered in Hidradenitis Suppurativa, With Epithelial-Mesenchymal-Transition Signals Ameliorated by Spleen Tyrosine Kinase Antagonism
Skin cells and immune cells change in a skin condition called hidradenitis suppurativa, and a certain treatment can improve these changes.
research Cerebral Ischemia Related to Isotretinoin; Venlafaxine-Induced Alopecia; Cognitive Dysfunction with Tolterodine; Retinal Artery Occlusion After Injection of Long-Acting Risperidone; Olanzapine-Induced Chylomicronemia Presenting as Pancreatitis; Metabolic Effects of the Atypical Antipsychotics – An Editorial; Another Drug-Induced Pancreatitis – This One Caused by a Tyrosine Kinase Inhibitor; Suicide Attempts Related to Antidepressant Medications
The conclusion is that healthcare professionals should report adverse drug reactions to improve medication safety and patient care.
research Activity of Sorafenib Against Desmoid Tumor/Deep Fibromatosis
Sorafenib is effective in treating Desmoid Tumor/Deep Fibromatosis.
research The PDGF/PDGFR Pathway as a Drug Target
The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.
research Cutaneous Reactions to Chemotherapeutic Drugs and Targeted Therapy for Cancer
Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
research Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
A woman's hair turned white after taking a cancer drug called dasatinib.
research An Overview of Management of Drug-Induced Hair and Nail Disorders
Cooling the scalp may prevent hair loss from chemotherapy, hair often grows back after treatment, and nail issues usually improve after stopping the drug.
research Hair Graying and Loss Induced by Imatinib Mesylate
A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Erosive Pustular Dermatosis of the Scalp Induced by Gefitinib: Case and Review of the Literature
An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.